Selected research
Industry Growth & Trends
Global Angiotensin Receptor Blockers (ARBs) Industry Growth and Trends Forecast to 2032
Market perspective
The global Angiotensin Receptor Blockers (ARBs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Angiotensin Receptor Blockers (ARBs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Angiotensin Receptor Blockers (ARBs) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Angiotensin Receptor Blockers (ARBs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Angiotensin Receptor Blockers (ARBs) include Teva Pharmaceutical, Sanofi, Jhonson and Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Angiotensin Receptor Blockers (ARBs) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Angiotensin Receptor Blockers (ARBs) market size, estimates, and forecasts are presented in terms of sales volume (k tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Angiotensin Receptor Blockers (ARBs) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Angiotensin Receptor Blockers (ARBs).
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Angiotensin Receptor Blockers (ARBs) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Angiotensin Receptor Blockers (ARBs) Market by Company
Teva Pharmaceutical
Sanofi
Jhonson and Johnson
Novartis
Merck
Eli Lilly
Pfizer
GSK
Bayer
Bristol-Myers Squibb
Astra Zeneca
Angiotensin Receptor Blockers (ARBs) Segment by Type
Valsartan
Telmisartan
Losartan
Irbesartan
Olmesartan
Azilsartan
Angiotensin Receptor Blockers (ARBs) Segment by Application
Cardiovascular Diseases
Kidney Diseases
Hypertension
Other
Angiotensin Receptor Blockers (ARBs) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiotensin Receptor Blockers (ARBs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Angiotensin Receptor Blockers (ARBs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiotensin Receptor Blockers (ARBs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Angiotensin Receptor Blockers (ARBs) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Angiotensin Receptor Blockers (ARBs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Valsartan
- Telmisartan
- Losartan
- Irbesartan
- Olmesartan
- Azilsartan
Applications
- Cardiovascular Diseases
- Kidney Diseases
- Hypertension
- Other
Companies covered
- Teva Pharmaceutical
- Sanofi
- Jhonson and Johnson
- Novartis
- Merck
- Eli Lilly
- Pfizer
- GSK
- Bayer
- Bristol-Myers Squibb
- Astra Zeneca
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Angiotensin Receptor Blockers (ARBs) Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales Estimates and Forecasts (2021-2032)
- 1.3 Angiotensin Receptor Blockers (ARBs) Market by Type
- 1.3.1 Valsartan
- 1.3.2 Telmisartan
- 1.3.3 Losartan
- 1.3.4 Irbesartan
- 1.3.5 Olmesartan
- 1.3.6 Azilsartan
- 1.4 Global Angiotensin Receptor Blockers (ARBs) Market Size by Type
- 1.4.1 Global Angiotensin Receptor Blockers (ARBs) Market Size Overview by Type (2021-2032)
- 1.4.2 Global Angiotensin Receptor Blockers (ARBs) Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Angiotensin Receptor Blockers (ARBs) Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Angiotensin Receptor Blockers (ARBs) Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Angiotensin Receptor Blockers (ARBs) Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Angiotensin Receptor Blockers (ARBs) Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Angiotensin Receptor Blockers (ARBs) Industry Trends
- 2.2 Angiotensin Receptor Blockers (ARBs) Industry Drivers
- 2.3 Angiotensin Receptor Blockers (ARBs) Industry Opportunities and Challenges
- 2.4 Angiotensin Receptor Blockers (ARBs) Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Angiotensin Receptor Blockers (ARBs) Revenue (2021-2026)
- 3.2 Global Top Players by Angiotensin Receptor Blockers (ARBs) Sales (2021-2026)
- 3.3 Global Top Players by Angiotensin Receptor Blockers (ARBs) Price (2021-2026)
- 3.4 Global Angiotensin Receptor Blockers (ARBs) Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Angiotensin Receptor Blockers (ARBs) Major Company Production Sites & Headquarters
- 3.6 Global Angiotensin Receptor Blockers (ARBs) Company, Product Type & Application
- 3.7 Global Angiotensin Receptor Blockers (ARBs) Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Angiotensin Receptor Blockers (ARBs) Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Angiotensin Receptor Blockers (ARBs) Players Market Share by Revenue in 2025
- 3.8.3 2025 Angiotensin Receptor Blockers (ARBs) Tier 1, Tier 2, and Tier 3
4 Angiotensin Receptor Blockers (ARBs) Regional Status and Outlook
- 4.1 Global Angiotensin Receptor Blockers (ARBs) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Angiotensin Receptor Blockers (ARBs) Historic Market Size by Region
- 4.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales in Volume by Region (2021-2026)
- 4.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales in Value by Region (2021-2026)
- 4.2.3 Global Angiotensin Receptor Blockers (ARBs) Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Angiotensin Receptor Blockers (ARBs) Forecasted Market Size by Region
- 4.3.1 Global Angiotensin Receptor Blockers (ARBs) Sales in Volume by Region (2027-2032)
- 4.3.2 Global Angiotensin Receptor Blockers (ARBs) Sales in Value by Region (2027-2032)
- 4.3.3 Global Angiotensin Receptor Blockers (ARBs) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Angiotensin Receptor Blockers (ARBs) by Application
- 5.1 Angiotensin Receptor Blockers (ARBs) Market by Application
- 5.1.1 Cardiovascular Diseases
- 5.1.2 Kidney Diseases
- 5.1.3 Hypertension
- 5.1.4 Other
- 5.2 Global Angiotensin Receptor Blockers (ARBs) Market Size by Application
- 5.2.1 Global Angiotensin Receptor Blockers (ARBs) Market Size Overview by Application (2021-2032)
- 5.2.2 Global Angiotensin Receptor Blockers (ARBs) Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Angiotensin Receptor Blockers (ARBs) Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Angiotensin Receptor Blockers (ARBs) Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Angiotensin Receptor Blockers (ARBs) Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Angiotensin Receptor Blockers (ARBs) Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Teva Pharmaceutical
- 6.1.1 Teva Pharmaceutical Company Information
- 6.1.2 Teva Pharmaceutical Business Overview
- 6.1.3 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 6.1.5 Teva Pharmaceutical Recent Developments
- 6.2 Sanofi
- 6.2.1 Sanofi Company Information
- 6.2.2 Sanofi Business Overview
- 6.2.3 Sanofi Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Sanofi Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 6.2.5 Sanofi Recent Developments
- 6.3 Jhonson and Johnson
- 6.3.1 Jhonson and Johnson Company Information
- 6.3.2 Jhonson and Johnson Business Overview
- 6.3.3 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 6.3.5 Jhonson and Johnson Recent Developments
- 6.4 Novartis
- 6.4.1 Novartis Company Information
- 6.4.2 Novartis Business Overview
- 6.4.3 Novartis Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Novartis Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 6.4.5 Novartis Recent Developments
- 6.5 Merck
- 6.5.1 Merck Company Information
- 6.5.2 Merck Business Overview
- 6.5.3 Merck Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Merck Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 6.5.5 Merck Recent Developments
- 6.6 Eli Lilly
- 6.6.1 Eli Lilly Company Information
- 6.6.2 Eli Lilly Business Overview
- 6.6.3 Eli Lilly Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Eli Lilly Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 6.6.5 Eli Lilly Recent Developments
- 6.7 Pfizer
- 6.7.1 Pfizer Company Information
- 6.7.2 Pfizer Business Overview
- 6.7.3 Pfizer Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Pfizer Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 6.7.5 Pfizer Recent Developments
- 6.8 GSK
- 6.8.1 GSK Company Information
- 6.8.2 GSK Business Overview
- 6.8.3 GSK Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 GSK Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 6.8.5 GSK Recent Developments
- 6.9 Bayer
- 6.9.1 Bayer Company Information
- 6.9.2 Bayer Business Overview
- 6.9.3 Bayer Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Bayer Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 6.9.5 Bayer Recent Developments
- 6.10 Bristol-Myers Squibb
- 6.10.1 Bristol-Myers Squibb Company Information
- 6.10.2 Bristol-Myers Squibb Business Overview
- 6.10.3 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 6.10.5 Bristol-Myers Squibb Recent Developments
- 6.11 Astra Zeneca
- 6.11.1 Astra Zeneca Company Information
- 6.11.2 Astra Zeneca Business Overview
- 6.11.3 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Product Portfolio
- 6.11.5 Astra Zeneca Recent Developments
7 North America by Country
- 7.1 North America Angiotensin Receptor Blockers (ARBs) Sales by Country
- 7.1.1 North America Angiotensin Receptor Blockers (ARBs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2026)
- 7.1.3 North America Angiotensin Receptor Blockers (ARBs) Sales Forecast by Country (2027-2032)
- 7.2 North America Angiotensin Receptor Blockers (ARBs) Market Size by Country
- 7.2.1 North America Angiotensin Receptor Blockers (ARBs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Angiotensin Receptor Blockers (ARBs) Market Size by Country (2021-2026)
- 7.2.3 North America Angiotensin Receptor Blockers (ARBs) Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Angiotensin Receptor Blockers (ARBs) Sales by Country
- 8.1.1 Europe Angiotensin Receptor Blockers (ARBs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2026)
- 8.1.3 Europe Angiotensin Receptor Blockers (ARBs) Sales Forecast by Country (2027-2032)
- 8.2 Europe Angiotensin Receptor Blockers (ARBs) Market Size by Country
- 8.2.1 Europe Angiotensin Receptor Blockers (ARBs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Angiotensin Receptor Blockers (ARBs) Market Size by Country (2021-2026)
- 8.2.3 Europe Angiotensin Receptor Blockers (ARBs) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Sales by Country
- 9.1.1 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market Size by Country
- 9.2.1 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Angiotensin Receptor Blockers (ARBs) Sales by Country
- 10.1.1 South America Angiotensin Receptor Blockers (ARBs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2026)
- 10.1.3 South America Angiotensin Receptor Blockers (ARBs) Sales Forecast by Country (2027-2032)
- 10.2 South America Angiotensin Receptor Blockers (ARBs) Market Size by Country
- 10.2.1 South America Angiotensin Receptor Blockers (ARBs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Angiotensin Receptor Blockers (ARBs) Market Size by Country (2021-2026)
- 10.2.3 South America Angiotensin Receptor Blockers (ARBs) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales by Country
- 11.1.1 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Market Size by Country
- 11.2.1 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Angiotensin Receptor Blockers (ARBs) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Angiotensin Receptor Blockers (ARBs) Value Chain Analysis
- 12.1.1 Angiotensin Receptor Blockers (ARBs) Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Angiotensin Receptor Blockers (ARBs) Production Mode & Process
- 12.2 Angiotensin Receptor Blockers (ARBs) Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Angiotensin Receptor Blockers (ARBs) Distributors
- 12.2.3 Angiotensin Receptor Blockers (ARBs) Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst